BioNTech’s Loss Is Wider Than Expected as Vaccine Sales Hurt
This article is for subscribers only.
BioNTech SE posted a quarterly loss that was wider than analysts foresaw amid low demand for Covid-19 vaccines and increased spending on developing new products.
Mainz, Germany-based BioNTech’s second-quarter loss was €3.36 ($3.68) a diluted share, according to a statement Monday. Sales of €128.7 million also missed analysts’ expectations.